Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24weeks of aromatase inhibition

Cancer Science

Volumn 102, Issue 4, 2011, Pages 858-865

  Toi, Masakazu ^a   Saji, Shigehira ^b,c   Masuda, Norikazu ^d   Kuroi, Katsumasa ^c   Sato, Nobuaki ^e   Takei, Hiroyuki ^f   Yamamoto, Yutaka ^g   Ohno, Shinji ^h   Yamashita, Hiroko ⁱ   Hisamatsu, Kazufumi ^j   Aogi, Kenjiro ^k   Iwata, Hiroji ^l   Takada, Masahiro ^a   Ueno, Takayuki ^a   Saji, Shigetoyo ^m   Chanplakorn, Niramol ⁿ   Suzuki, Takashi ⁿ   Sasano, Hironobu ⁿ  

^a KYOTO UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

^e Niigata Cancer Center   (Japan)

^f SAITAMA CANCER CENTER   (Japan)

^g KUMAMOTO UNIVERSITY   (Japan)

^h NATIONAL KYUSHU CANCER CENTER   (Japan)

ⁱ NAGOYA CITY UNIVERSITY HOSPITAL   (Japan)

^j HIROSHIMA CITY ASA HOSPITAL   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^l AICHI CANCER CENTER HOSPITAL   (Japan)

^m Japanese Foundation for Multidisciplinary Treatment of Cancer   (Japan)

ⁿ TOHOKU UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AROMATASE; ASPARTATE AMINOTRANSFERASE; CREATININE; ESTROGEN RECEPTOR; EXEMESTANE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; HOT FLUSH; HUMAN; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; ANDROSTADIENES; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79952766466     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01867.x     Document Type: Article

References (25)

1. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-85.
2. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; (30): 96-102.
3. van der Hage JA, van de Velde CJ. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19: 4224-37.
4. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-74.
5. Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-27.
6. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-44.
7. Aapro M, Monfardini S, Jirillo A, Basso U. Management of primary and advanced breast cancer in older unfit patients (medical treatment). Cancer Treat Rev 2009; 35: 503-8.
8. Mlineritsch B, Tausch C, Singer C et al. Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat 2008; 112: 203-13.
9. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527-32.
10. Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006; 106: 2095-103.
11. Takei H, Suemasu K, Inoue K et al. Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Breast Cancer Res Treat 2008; 107: 87-94.
12. Semiglazov VF, Semiglazov VV, Dashyan GA et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007; 110: 244-54.
13. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. [Cited September 2010.] Available from URL: .
14. Barnadas A, Gil M, González S, et al. Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. Br J Cancer 2009; 100: 442-9.
15. Ring AE, Smith IE, Ashley S et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004; 91: 2012-7.
16. Ellis MJ, Tao Y, Luo J et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008; 100: 1380-8.
17. Dowsett M, Smith IE, Ebbs S et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99: 167-70.
18. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-81.
19. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45.
20. Bouzubar N, Walker KJ, Griffiths K et al. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 1989; 59: 943-7.
21. Miller WR, White S, Dixon JM et al. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 2006; 94: 1051-6.
22. Olson JA Jr, Budd GT, Carey LA et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg 2009; 208: 906-14.
23. Dixon JM, Renshaw L, Macaskill EJ et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 2009; 113: 145-51.
24. Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3784-96.
25. Miller WR. Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. J Steroid Biochem Mol Biol 2010; 118: 273-6.